No effect of carvedilol on nitric oxide generation in phagocytes but modulation of production of superoxide ions

Biochemical Pharmacology

Volumn 59, Issue 8, 2000, Pages 1007-1013

  Åsbrink, Sara ^a   Zickert, Agneta ^a   Bratt, Johan ^a   Gyllenhammar, Hans ^a   Palmblad, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carvedilol; Chemotaxis; Endothelial cells; Neutrophils; Nitric oxide; Superoxide ions

Indexed keywords

CALCIMYCIN; CARVEDILOL; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LIPOXIN A; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME REGULATION; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CALCIUM; CARBAZOLES; CHEMOTAXIS, LEUKOCYTE; CYTOCHROME C GROUP; FREE RADICAL SCAVENGERS; GTP-BINDING PROTEINS; HUMANS; MICE; NEUTROPHILS; NITRIC OXIDE; OXIDATION-REDUCTION; PHAGOCYTES; PHOSPHOLIPASE C; PROPANOLAMINES; SUPEROXIDES;

EID: 0033952160     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00393-7     Document Type: Article

References (28)

1. Frishman W.H. Carvedilol. N Engl J Med. 339:1998;1759-1765.
2. Feuerstein G.Z., Bril A., Ruffolo R.R. Jr. Protective effects of carvedilol in the myocardium. Am J Card. 80:1997;41L-45L.
3. Ruffolo R.R. Jr, Feuerstein G.Z. Pharmacology of carvedilol. Rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther. 11:(Suppl 1):1997;247-256.
4. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Eng J Med. 334:1996;1349-1355.
5. Cohn J.N., Fowler M.B., Bristow M.R., Colucci W.S., Gilbert E.M., Kinahl V., Krueger S.K., Lejemtel T., Narahara K.A., Packer M., Young S.T., Holcslaw T.L., Lukas M.A. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail. 3:1997;173-179.
6. Yue T., McKenna P.J., Ruffolo R.R. Jr, Feuerstein G. Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol. 214:1992;277-280.
7. Yue T., McKenna P.J., Lysko P.G., Ruffolo R.R. Jr, Feuerstein G.Z. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis. 97:1992;209-216.
8. Yue T., McKenna P.J., Gu J., Cheng H., Ruffolo R.R. Jr, Feuerstein G.Z. Carvedilol, a new vasodilating beta adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils. Cardiovasc Res. 28:1994;400-406.
9. Lopez B.L., Christopher T.A., Yue T., Ruffolo R.R. Jr, Feuerstein G.Z., Ma X. Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Pharmacology. 51:1995;165-173.
10. Lärfars G., Gyllenhammar H. Stimulus-dependent transduction mechanisms for nitric oxide release in human polymorphonuclear neutrophil leukocytes. J Lab Clin Med. 132:1998;54-60.
11. 4 in human polymorphonuclear leukocytes. Blood. 93:1999;1399-1405.
12. 4-induced polymorphonuclear neutrophil-dependent cytotoxicity to human vascular endothelium in vitro. Arthritis Rheum. 38:1995;768-776.
13. 4 induces neutrophil-dependent cytotoxicity for human endothelial cells. Scand J Immunol. 39:1994;351-354.
14. Bratt J., Palmblad J. Inhibition of neutrophil-dependent cytotoxicity for human endothelial cells by antirheumatic drugs. J Lab Clin Med. 128:1996;552-560.
15. Harvath L., Aksamit R.R. Oxidized N-formylmethionyl-leucyl-phenylalanine Effect on the activation of human monocyte and neutrophil chemotaxis and superoxide production. J Immunol. 133:1984;1471-1476.
16. Fraticelli A., Serrano C.V., Bochner B.S., Capogrosi M.C., Zweier J.L. Hydrogen peroxide and superoxide modulate leukocyte adhesion molecule expression and leukocyte endothelial adhesion. Biochim Biophys Acta. 1310:1996;251-259.
17. Corriveau C.C., Madara P.J., Van Dervort A.L., Tropea M.M., Wesley R.A., Danner R.L. Effects of nitric oxide on chemotaxis and endotoxin-induced interleukin-8 production in human neutrophils. J Infect Dis. 177:1998;116-126.
18. Malawista S.E., de Boisfleury Chevance A. Chemotaxis by human neutrophils and their cytokineplasts treated with inhibitors of nitric oxide synthase No suppression of orientation or trajectory. J Leukoc Biol. 61:1997;58-62.
19. VanUffielen B.E., de Koster B.M., Van den Broek P.J., VanSteveninck J., Elferink J.G. Modulation of neutrophil migration by exogenous gaseous nitric oxide. J Leukoc Biol. 60:1996;94-100.
20. Lerner R., Lindström P., Berg A., Johansson E., Rosendahl K., Palmblad J. Development and characterization of essential fatty acid deficiency in human endothelial cells in culture. Proc Natl Acad Sci U S A. 92:1995;1147-1151.
21. 4 induced hyperadhesiveness of endothelial cells for neutrophils. J Immunol. 152:1994;262-269.
22. 4 and N-formyl-methionyl-leucyl-phenylalanine. Photochem Photobiol. 49:1989;217-223.
23. Lärfars G., Gyllenhammar H. Measurement of methemoglobin formation from oxyhemoblobin. A real-time, continuous assay of nitric oxide release by human polymorphonuclear leukocytes. J Immunol Methods. 184:1995;53-62.
24. Feelisch M., Noack E.A. Nitric oxide (NO) formation from nitrovasodilators occurs independently of hemoglobin or non-heme iron. Eur J Pharmacol. 142:1987;465-469.
25. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem. 126:1982;131-138.
26. 4-induced neutrophil-dependent cytotoxicity for human endothelial cells. J Lab Clin Med. 126:1995;36-43.
27. Palmblad J., Wannemacher R.W., Salem N. Jr, Kuhns D.B., Wright D.G. Essential fatty acid deficiency and neutrophil function Studies of lipid-free total parenteral nutrition in monkeys. J Lab Clin Med. 111:1988;634-644.
28. Yue T.L., Wang X., Gu J.L., Ruffolo R.R. Jr, Feuerstein G.Z. Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol. 294:1995;585-591.